
April 15 (Reuters) -
TORAGEN- POSITIVE SAFETY DATA FROM PHASE 1 TRIAL OF TGN-S11, IN PATIENTS WITH CANCERS ASSOCIATED WITH HPV
TORAGEN- EVIDENCE OF ACTIVITY IS IDENTIFIED FOR TGN-S11 AS A MONOTHERAPY AND IN COMBINATION WITH KEYTRUDA
TORAGEN- PHASE 1 TRIAL MET BOTH PRIMARY ENDPOINTS OF PROVING SAFETY AND REACHING MAXIMUM TOLERATED DOSE OF TGN-S11
Further company coverage: [ ]